A Kentucky overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
37.2% of Kentucky adults had obesity in 2024 — 10th-highest among the 49 states with a valid 2024 BRFSS estimate (Tennessee's 2024 value is CDC-suppressed for insufficient sample size) 1. A second metabolic-risk indicator sits alongside it: 28.0% of Kentucky adults reported no leisure-time physical activity in 2024 (95% CI 26.5–29.4%, n=7,439) 1.
Kentucky's population reached 4,588,372 in the Vintage 2024 estimates, up from 4,506,302 at the April 1, 2020 Census base — roughly 82,000 more residents (+1.8%) in four years 2.
No. Kentucky Medicaid does not cover any GLP-1 or GIP medication for the indication of obesity or weight loss. The state's Preferred Drug List and Prior Authorization criteria (MedImpact, the single PBM covering both fee-for-service and all six Medicaid MCOs) state three times, verbatim: "Drugs used for anorexia, weight loss, or weight gain are excluded from coverage" 34.
Diabetes-indicated products — Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, exenatide, and liraglutide — are Preferred only with a confirmed Type 2 diabetes diagnosis (ICD-10 code plus a qualifying A1c of 6.5% or higher); the combination products Soliqua and Xultophy instead require documented concurrent use of a long-acting insulin with a GLP-1 agonist — a step-therapy test that is likewise diabetes-specific, not the ICD-10+A1c standard applied to the others 4.
Two products have narrow, non-weight-loss pathways: Wegovy (semaglutide), effective January 3, 2026, is approved only for cardiovascular-risk reduction (age 45+, established cardiovascular disease, BMI 27+) or for MASH/NASH with liver fibrosis 5; Zepbound (tirzepatide), under 2025 criteria, is approved only for moderate-to-severe obstructive sleep apnea (BMI 30+, confirmed OSA, a failed 3-month trial of CPAP/BiPAP/APAP) 6. Both require no history of diabetes. Saxenda does not appear on any Kentucky Medicaid PDL, PA-criteria, or quantity-limit document 34. Net effect: there is no approval pathway for a Kentucky Medicaid enrollee to obtain any GLP-1 medication covered specifically for obesity or weight loss.
Because the weight-loss indication is excluded outright, a Kentucky Medicaid enrollee pursuing GLP-1 treatment for obesity pays out of pocket regardless of where in the state they live.
Astra's price in Kentucky is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no Kentucky-specific price, discount, or surcharge.
Kentucky's statewide uninsured rate, median household income, and HRSA shortage-area count were not obtained in this research pass. Those are confirmed data gaps, not estimates, and no placeholder figure is shown in their place.
Kentucky Medicaid's coverage gaps leave weight-management care concentrated in cash-pay and telehealth channels, at the same time 28.0% of Kentucky adults report no leisure-time physical activity (2024, CDC BRFSS) — a second metabolic-risk indicator layered on the state's 37.2% obesity rate 1. What is documented is the coverage structure above: a Kentucky Medicaid enrollee pursuing GLP-1 treatment for weight loss pays out of pocket regardless of where in the state they live — the exact gap licensed telehealth is built to close, standing in for a specialist visit without requiring one.
Telehealth prescribing in Kentucky is governed by the Kentucky Board of Medical Licensure (kbml.ky.gov). This page stops there: no specific Kentucky regulation number or requirement is asserted until it has been verified against a primary source.
Astra is licensed to treat patients in Kentucky and in all 50 states.
Astra treats patients in Kentucky through state-licensed physicians.
Lexington and Louisville city pages carry local access and pricing detail.
No. Kentucky Medicaid's Prior Authorization criteria state three times, verbatim, that "drugs used for anorexia, weight loss, or weight gain are excluded from coverage" (MedImpact PA Criteria, pp. 155-158, August 2026). Ozempic and similar GLP-1 products are covered only with a confirmed Type 2 diabetes diagnosis; Wegovy is covered only for cardiovascular-risk reduction or MASH; Zepbound is covered only for obstructive sleep apnea. None of these pathways is a weight-loss indication.
Kentucky Medicaid's standalone PA pathways for Wegovy (semaglutide, eff. 1/3/2026) and Zepbound (tirzepatide, 2025 criteria) were built around cardiovascular risk, MASH, and sleep apnea specifically. Each pathway explicitly requires the patient have no history of diabetes, and neither is written as, or convertible to, a weight-loss authorization — the state's own PDL and PA documents draw that line explicitly.
No. Astra prices semaglutide and tirzepatide the same nationwide: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans billed annually ($816 and $1,416 respectively). There is no Kentucky-specific price, discount, or surcharge.
Yes. Astra is licensed to serve patients in all 50 states, including Kentucky, so residents anywhere in the state — not just Lexington or Louisville — can complete an intake and receive treatment through telehealth without an in-person specialist visit.
Because Kentucky Medicaid does not cover GLP-1 treatment for weight loss under any of the pathways above, a Medicaid enrollee paying out of pocket faces the same $68/$118 monthly Astra pricing as anyone else in the state. Astra is not a Medicaid-covered benefit here, and no telehealth provider can make Kentucky Medicaid cover an indication its own PA criteria excludes.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.